CALGARY, Alberta, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation")
(TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. A total of 126,864,830
shares (approximately 71.50% of outstanding common shares) were represented in person or by proxy.
During business proceedings at the Meeting, shareholders elected six (6) Board members until the next annual
meeting. The voting results of shares represented at the Meeting for individual directors were as follows:
| |
|
|
|
|
| |
Votes For |
Votes Withheld |
Percent For |
Percent Withheld |
| |
|
|
|
|
| Donald J. McCaffrey |
119,460,894 |
341,143 |
99.72 |
0.28 |
| Norma Biln |
119,660,378 |
141,659 |
99.88 |
0.12 |
| Shawn Lu |
119,594,448 |
207,589 |
99.83 |
0.17 |
| Kelly McNeill |
119,661,978 |
140,059 |
99.88 |
0.12 |
| Dr. Eldon Smith |
119,681,648 |
120,389 |
99.90 |
0.10 |
| Kenneth Zuerblis |
119,615,048 |
186,989 |
99.84 |
0.16 |
| |
|
|
|
|
Resverlogix shareholders approved all resolutions, including an amendment to the Corporation’s articles to
potentially consolidate the issued and outstanding common shares, outlined in the Notice of Meeting and Management Information
Circular dated July 27, 2018 (the “Information Circular”). The Information Circular is available on SEDAR at www.sedar.com, and on
the Resverlogix website at www.resverlogix.com.
A webcast archive of the executive presentation portion of the Meeting is available here.
The Corporation also announces that it expects to file its unaudited interim Consolidated Financial Statements
and Management's Discussion & Analysis for the quarter ended July 31, 2018 with Canadian securities regulatory authorities on
September 14, 2018. These materials will be available on the Resverlogix website, and on SEDAR, shortly after being filed.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing
genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition
of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk
cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described
safety profile.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: www.resverlogix.com
